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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2015, KaohsiuAbstract To investigate the incidence and prognostic factors of ethambutol-related optic
neuropathy (EON) in one medical center of southern Taiwan, a retrospective chart review
study with 4803 newly diagnosed tuberculosis cases from January 2002 to July 2011 at one
medical center hospital in southern Taiwan were reviewed. Of these patients, 1004 had
ophthalmic records. Sixty-two cases (1.29%) experienced visual impairment and were diag-
nosed as EON with mean visual acuity of 0.86  0.69 by logMAR. Sixteen of the 62 patients
had a follow-up time > 6 months. Of these, eight patients (50%) showed visual improvement
(an increase in visual acuity of  2 Snellen lines) after ethambutol was discontinued. Another
eight patients (50%) showed no visual improvement. We analyzed multiple factors between the
patients with and without visual improvement by logistic regression, including body weight,
daily dose of ethambutol, duration of ethambutol use, cumulative dose of ethambutol, renal
function, underlying disease of diabetes mellitus, hypertension, and initial visual acuity
showed no statistically significant difference. In conclusion, the incidence of EON was
1.29%. Half of the patients showed visual improvement after discontinuation of ethambutol,
and no obvious prognostic factors were found to facilitate the vision recovery. Ethambutol
should be discontinued as soon as EON is suspected.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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Tuberculosis is one of the most important systemic in-
fections throughout the world, and it is caused by Myco-
bacterium tuberculosis [1]. Tuberculosis should be treated
with the combination of antituberculous drugs. Ethambutol
has been used to treat tuberculosis since the 1960s, but the
related visual impairment was recognized soon after its
introduction [2]. Ethambutol-related optic neuropathy
(EON) has become an established ocular complication and
may lead to permanent visual loss. There have been several
studies regarding the incidence of EON in different coun-
tries. The incidence was w1% and correlated with dosage
[3e5]. However, no literature was available in southern
Taiwan. The purpose of this study is to investigate the
incidence and clinical features of EON in one medical
center of southern Taiwan.Table 1 Characteristics of the 62 patients with
ethambutol-related optic neuropathy.
Variables N Mean  SD
Age (y) 62 70.02  14.26Methods
We conducted a retrospective chart review of patients
diagnosed and filed as tuberculosis in the Infection Control
Center from January 2002 to July 2011 at our hospital.
Patients who experienced visual impairment after the
initiation of ethambutol use and diagnosed as EON based on
ophthalmic records were collected. The visual symptoms
and signs included decreased visual acuity, impaired color
vision by Ishihara color plate, or abnormal results of visual
field and/or flash and pattern visual evoked potential ex-
aminations. Patients with vision impairment related to
other ophthalmologic problems such as cataract, retinal
disease, glaucoma, and other cause of optic neuropathy
were excluded. Data variables included age, sex, medical
history, date of diagnosis, treatment, visual acuity, color
vision, slit lamp biomicroscopy, fundus and other
ophthalmic examination if eligible. Patients diagnosed as
EON with a follow-up time of > 6 months were further
investigated for surveying the prognostic factor of EON.
SPSS Statistics software version 17 (SPSS Inc., Chicago,
IL, USA) was used for analysis of results. Descriptive sta-
tistics were expressed as mean, with standard deviation.
Means of normally distributed variables were compared
with logistic regression analysis. Odds ratios were also
calculated. The p value or 95% confidence interval was
calculated as appropriate. For statistical analysis, decimal
fractions of visual acuity were converted to a logarithmic
scale (the logarithm of the minimal angle of resolution).
The Institutional Review Board and Ethics Committee of
Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
approved this study, which adhered to the tenets of the
Declaration of Helsinki; patient consent was not required.Weight (kg) 62 56.59  11.79
EMB daily dose (mg/d) 62 16.06  4.36
EMB duration (mo) 62 5.94  4.06
EMB cumulative
dose (mg/kg)
62 2820.02  2157.39
Initial VA logMAR 124 (eyes) 0.86  0.69
Initial color
(Ishihara color test)
112 (eyes) 7.23  8.53
Follow-up time (mo) 62 5.87  11.61Results
In the retrospective chart review, 4803 cases were diag-
nosed and filed as tuberculosis in the Infection Control
Center of Kaohsiung Veterans General Hospital, Kaohsiung,
Taiwan from January 2002 to July 2011, of whom 1004 had
ophthalmic records. Sixty-two patients (1.29%) experienced
visual impairment and were diagnosed as EON. Mean age ofaffected patients was 70.02  14.26 years (range, 27e90
years). Forty-one were male and 21 female. Mean body
weight was 56.59  11.79 kg (range. 30.7e80.9 kg). Mean
ethambutol daily dose was 16.06  4.36 mg/kg (range,
6.3e32.6 mg/kg). Average duration of ethambutol use was
5.94  4.06 months (range, 1e21 months). Mean etham-
butol cumulative dose was 2820.02  2157.39 mg/kg
(range, 270e10,749 mg/kg). Average follow-up time was
5.87  11.61 months (range, 0e60 months; Table 1).
Twenty-one of the 62 patients had visual field examina-
tions; seven showed constricted, seven showed general
decrease, and five showed paracentral scotoma. In the nine
patients who had flash and pattern visual evoked potentials
tests, delayed latency was seen in five patients and poor
waveform was seen in four.
Of the above 62 patients, 16 were followed-up in our
ophthalmic clinic for > 6 months. Fifteen patients suffered
from primary pulmonary tuberculosis, and one patient
suffered from primary bone marrow tuberculosis. Their
ethambutol dose ranged from 400 mg/d to 1600 mg/d. Eight
patients (50%) showed visual improvement (an increase in
visual acuity of  2 Snellen lines) after ethambutol was
discontinued; another eight patients (50%) showed no visual
improvement after discontinuation of ethambutol. The
detailed clinical presentations of the 16 patients diagnosed
as EON with a follow-up time of > 6 months are listed in
Table 2.
The mean age of the 16 patients was 76.75  7.21 years
(range, 59e85 years). Their mean body weight was
57.91  12.29 kg (range, 35.0e80.0 kg). Mean ethambutol
daily dose was 16.37  4.46 mg/kg (range, 7.3e24.2 mg/
kg), average duration of ethambutol use was 7.56  4.88
months (range, 1e21 months), and mean ethambutol cu-
mulative dose was 3479.46  2189.16 mg/kg (range,
615e9450 mg/kg). Mean glomerular filtration rate was
46.38  19.19 mL/min (range, 5.5e80.0 mL/min). Average
follow-up time was 19.44  16.65 months (range, 6e60
months). The visual acuity improved from 0.84  0.39 to
0.28  0.21 by logMAR in the visual improved group and only
changed from 1.07  0.87 to 0.96  0.76 by logMAR in the
nonimproved group (Table 3).
Multiple factors including age, sex, body weight,
ethambutol daily dose, ethambutol duration, ethambutol
cumulative dose, glomerular infiltration rate, underlying
disease of diabetes, hypertension, and initial visual acuity
Table 2 Clinical presentation of the 16 patients diagnosed with ethambutol-related optic neuropathy with a follow-up time of more than 6 months.
Case Sex Age
(y)
Weight
(kg)
Tuberculosis
involved
organ
EMB
dose
(mg/kg)
EMB
daily
dose
(mg/kg)
EMB
duration
(mo)
EMB
cumulative
dose
(mg/kg)
Glomerular
filtration
rate
(mL/min)
Follow-up
time
(mo)
Systemic
disease
OD OS Improvement
Initial
VA
Final
VA
Initial
color
Final
color
Initial
VA
Final
VA
Initial
color
Final
color
1 M 82 52.4 Lung 800 15.3 6 2748 52.8 13 DM, colon
cancer
6/20 6/20 21/21 d 6/15 6/20 21/21 d d
2 M 85 68.0 Lung 800 11.8 13 4588 43.3 46 DM, HTN,
Sicca
syndrome
6/20 6/6 1/21 21/21 6/60 6/8.6 0/21 7/21 OU
3 M 84 58.5 Lung 1200 20.5 1 615 16.9 60 HTN 6/12 6/15 2/21 d 6/12 6/20 2/21 d d
4 F 76 42.0 Lung 800 19.0 8 4571 63.5 17 Colon
cancer
6/60 3/60 d d 1/60 4/60 d d d
5 M 77 58.0 Lung 1200 20.7 1 621 63.4 32 d 6/30 6/30 12/21 6/21 6/30 6/30 13/21 15/21 d
6 M 82 79.5 Lung 1200 15.1 5 2264 42.7 9 Colon
cancer
6/30 6/7.5 0/21 21/21 3/60 6/8.6 1/21 21/21 OU
7 M 84 52.5 Lung 800 15.2 12 5486 45.4 43 d 6/30 6/12 9/21 20/21 6/30 6/12 11/21 19/21 OU
8 F 76 55.1 Bone
marrow
400 7.3 6 1307 5.5 10 ESRD 6/30 6/8.6 1/21 19/21 6/60 6/12 1/21 19/21 OU
9 M 67 63.1 Lung 800 12.7 6 2282 80.0 17 Polymyositis 6/60 6/30 7/21 d 4/60 6/20 8/21 d OS
10 M 78 64.4 Lung 800 12.4 9 3354 34.7 6 DM, HTN,
CAD
4/60 6/60 0/21 1/21 CF 1/60 0/21 0/21 d
11 M 83 45.0 Lung 800 17.8 9 4800 32.4 15 d CF CF 0/21 0/21 CF CF 0/21 0/21 d
12 M 72 58.0 Lung 800 13.8 8 3310 32.2 7 d 6/60 6/60 5/21 5/21 6/60 6/30 5/21 5/21 d
13 F 77 35.0 Lung 800 22.9 7 4800 52.1 6 d 6/12 6/20 18/21 21/21 6/7.5 6/8.6 21/21 21/21 d
14 M 78 49.5 Lung 1200 24.2 3 2182 53.3 15 HTN 5/60 6/15 0/21 1/21 1/60 6/30 0/21 1/21 OU
15 M 68 65.6 Lung 1200 18.3 6 3293 54.7 6 d 6/15 6/7.5 5/21 21/21 6/15 6/7.5 5/21 21/21 OU
16 M 59 80.0 Lung 1200 15.0 21 9450 69.2 9 DM, HTN 6/30 6/15 2/21 d 6/10 6/7.5 3/21 d OU
OD Z right eye; OS Z left eye; OU Z both eyes; VA Z visual acuity; CF Z counting fingers; DM Z diabetes mellitus; HTN Z hypertension; CAD Z coronary artery disease.
Table 3 Characteristics of the 16 ethambutol-related optic neuropathy patients with or without visual improvement for a
follow-up time of more than 6 months.
Total
(n Z 16)
Visual improvement (n Z 8) No visual improvement (n Z 8)
Age (y) 76.75  7.21 74.88  9.33 78.63  4.07
Sex (male/female) 13/3 7/1 6/2
Weight (kg) 57.91  12.29 64.16  11.57 51.66  10.04
EMB daily dose (mg/kg) 16.37  4.46 14.95  4.96 17.80  3.67
EMB duration (mo) 7.56  4.88 9.00  5.95 6.13  3.31
EMB cumulative dose (mg/kg) 3479.46  2189.16 3856.50  2648.83 3102.38  1711.18
Glomerular filtration rate (mL/min) 46.38  19.19 49.26  22.03 43.50  16.87
Diabetes mellitus 4 2 2
Hypertension 5 3 2
Follow-up time (mo) 19.44  16.65 19.38  15.92 19.50  18.46
Initial VA logMAR
(32 eyes)
0.95  0.67 0.84  0.39 1.07  0.87
Final VA logMAR
(32 eyes)
0.62  0.65 0.28  0.21 0.96  0.76
EMB Z ethambutol; VA Z visual acuity.
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visual improved group and nonimproved group, no statisti-
cally significant difference was found between the above
factors (Table 4).Discussion
In our study, the incidence of EON was 1.29%. Compared
with previous studies, a 1.5% incidence of EON was reported
in a recent study from Korea [5], and earlier studies re-
ported an incidence of around 1% [2,6,7]. Ezer et al [8]
reported a meta-analysis searching Cochrane, Embase,
and PubMed electronic databases from 1965 to February
2011 for studies regarding tuberculosis patients treated
with ethambutol, any visual impairment occurred in 22.5/
1000 persons receiving ethambutol at standard doses for up
to 9 months, and permanent impairment in 2.3/1000 [8].
The result of our study was comparable to previous studies,
but the actual incidence of EON might be underestimated.
In the 4803 cases diagnosed and filed as tuberculosis, onlyTable 4 Analysis of possible factors contributing to visual impro
a follow-up time of more than 6 months (adjusted for age and se
Variables Adjusted odds ratio
Weight (kg) 1.153
EMB daily dose (mg/kg) 0.851
EMB duration (mo) 1.166
EMB cumulative dose (mg/kg) 1.000
Glomerular filtration rate (mL/min) 0.999
Diabetes mellitus 0.739
Hypertension 0.284
Initial VA logMAR 0.544
p < 0.05 was considered to be significant.
EMB Z ethambutol; VA Z visual acuity.1004 patients had ophthalmic records. We believe that the
incidence of EON should be much lower in the residual 3799
patients without ophthalmic records, but if any EON was
overlooked among these patients, the accurate incidence
of EON might be higher.
The visual function recovery after discontinuation of
ethambutol was seen in eight of the 16 patients with a
follow-up time of > 6 months. The recovery rate was 50%.
In previous studies, Kumar et al [9] described a series of
seven consecutive patients with severe visual deficit due to
ethambutol toxicity, only 42.2% (3 of the 7 patients) ach-
ieved a visual recovery of better than 20/200 after an
average follow-up of 8.3  2.1 months after stoppage of the
drug [9]. Lim [3] described three cases of EON presented
with bitemporal hemianopia, and only one case recovered
visual function after stopping ethambutol use. Subsequent
improvement was mild in another two cases. Tsai and Lee
[10] described 10 consecutive patients with severe visual
defects due to ethambutol toxicity. Five patients (50%)
experienced visual improvement after 1e3 years follow-up,
and the other five showed no recovery. Lee et al [5]vement in ethambutol-related optic neuropathy patients with
x).
95% confidence interval p
Lower Upper
0.975 1.363 0.095
0.655 1.105 0.226
0.853 1.596 0.336
0.999 1.001 0.665
0.936 1.066 0.969
0.059 9.260 0.815
0.028 2.839 0.284
0.088 3.354 0.512
362 S.-C. Chen et al.reported a retrospective chart review study in Korea and
only slightly less than one third of patients showed
improvement in visual function after discontinuing etham-
butol. Visual function recovery rate after discontinuation of
ethambutol was comparable in our study to previous
reports.
In this study, the mean ethambutol daily dose of patients
developing EON was 16.06  4.36 mg/kg, while previous
study suggested an increased risk of EON if the daily dose of
ethambutol was over 15 mg/kg [11]. In a recent nationwide
population-based study about EON reported by Chen et al
[12], age, hypertension, and renal diseases are risk factors
for EON, but higher average daily dose was not correlated
with an increased risk for EON in the Taiwanese population
[12].
In the 16 patients with a follow-up time of > 6 months,
eight showed visual improvement with visual acuity
improved from 0.84  0.39 to 0.28  0.21 by logMAR, and
eight showed no visual improvement with visual acuity only
changed from 1.07  0.87 to 0.96  0.76 by logMAR. No
statistically significant difference was found in the age,
sex, body weight, ethambutol daily dose, ethambutol
duration, ethambutol cumulative dose, renal function,
underlying disease of diabetes mellitus, hypertension, and
initial visual acuity between patients with visual improve-
ment and nonimprovement.
In the report of Kumar et al [9], three patients achieved
a visual recovery from seven consecutive patients with se-
vere visual deficit due to ethambutol toxicity. There were
no predisposing or risk factors to contribute toward the
poor visual gain [9]. In another case series from Tsai et al
[10], there were also no predisposing or risk factors to
contribute to the poor visual gain after stoppage of
ethambutol use. Regarding the reversibility of EON, no
obvious prognostic factors were mentioned in previous re-
ports. In our study, no obvious prognostic factor could be
identified maybe due to the small sample size with only 16
cases included. The body weight of the visual improved
group seemed to be heavier than the nonimproved group,
but p > 0.05 remained (p Z 0.095). Most of the patients
with EON were elderly patients. Maybe among these elderly
patients, the general nutrition status of heavier patients
was better, leading to better visual improvement in EON
after discontinuation of ethambutol use. It reminds us that
in the treatment of tuberculosis with ethambutol, we
should be very careful in the dose of ethambutol used in
leaner patients.
The ethambutol daily dose is higher in the group of pa-
tients without visual improvement than the patients with
visual improvement (17.80  3.67 mg/d vs.
14.94  4.96 mg/d; p Z 0.226). Daily dose of visual
improvement group was < 15 mg/kg, and daily dose of the
nonimprovement group was > 15 mg/kg. Coincidently,
previous study also suggested an increased risk of EON if the
daily dose of ethambutol was > 15 mg/kg [11]. In the
treatment course with ethambutol, the daily dose of
ethambutol should be better controlled within no more
than 15 mg/kg.We also noted a trend that older patients show poorer
visual recovery. The age is higher in the group of patients
without visual improvement than the patients with visual
improvement (78.63  4.07 vs. 74.88  9.32). We have to
pay more attention in the monitoring of side effects of EON
during the use of ethambutol in older patients.
Conclusion
In this study, we estimated that the incidence of EON in
tuberculosis patients receiving ethambutol treatment was
at least 1.29%. The vision recovery rate after discontinua-
tion of ethambutol was 50% at 6-month follow-up.
Regarding the recovery of visual function in EON patients,
no statistically significance was observed in the body
weight, diabetes mellitus, hypertension, renal function,
daily dose, duration, or cumulative dose of ethambutol use.
There was a trend that lower body weight, age, and higher
daily dose of ethambutol use were related to poorer visual
recovery, but this was not significant. Since half of patients
with EON suffered from irreversible loss of visual function,
ethambutol should be discontinued promptly if EON was
suspected to prevent further optic nerve damage.
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